Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. during the specified Class Period, indicating potential misrepresentation by the company regarding its drug candidate and regulatory approvals [1][5]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against uniQure - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is alleged that the company's statements regarding its business operations and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its drug candidate AMT-130 and its regulatory prospects with the FDA [1][11]. Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, including Huntington's disease (HD) [3]. - The company's leading drug candidate, AMT-130, aims to slow the progression of HD, a fatal inherited disorder with no existing cure [4]. Clinical Trials and FDA Interaction - uniQure completed patient enrollment for two ongoing Phase I/II clinical trials for AMT-130, known as the Pivotal Study, in March 2022 [4]. - The FDA had previously agreed that the Pivotal Study would not include a placebo comparator, allowing results to be compared to an external historical dataset, ENROLL-HD, for potential BLA submission [5]. Investor Communication and Stock Performance - On September 24, 2025, uniQure announced topline results from the Pivotal Study, leading to a significant increase in share price from $13.66 to $47.50, a nearly 250% rise [7][8]. - By October 29, 2025, shares were trading above $70.00, and the company raised approximately $345 million through a public offering shortly after the positive study results [9]. Allegations of Misrepresentation - The lawsuit alleges that uniQure misrepresented the FDA's approval of the Pivotal Study design and downplayed the likelihood of delays in the BLA timeline, leading to inflated stock prices based on misleading information [11]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the study data was adequate for BLA submission, resulting in a stock price drop of over 49% [10]. Legal Process for Investors - Investors who acquired uniQure shares during the class period may seek to be appointed as lead plaintiffs by April 13, 2026, to represent the class in the lawsuit [2][12].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by April 13, 2026 [4]. Group 1: Allegations Against uniQure - The complaint alleges that uniQure and its executives made false and misleading statements regarding the FDA approval of the design of the Pivotal Study and downplayed the likelihood of delays in the BLA timeline [6]. - It is claimed that the results from the Pivotal Study were not fully approved by the FDA, and the company would need to conduct additional studies to support its BLA submission [6]. - The disclosure on November 3, 2025, revealed that the FDA no longer agreed that the data from the Phase I/II AMT-130 studies would be adequate for BLA submission, contradicting previous statements about the path toward accelerated approval [7]. Group 2: Financial Impact - Following the disclosure, uniQure's share price fell by $33.40, a decline of over 49%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [8]. Group 3: Legal Proceedings - The role of lead plaintiff in the class action is designated to the investor with the largest financial interest who is also typical of class members, with the option for any member to move the court to serve as lead plaintiff [9]. - Faruqi & Faruqi encourages anyone with information regarding uniQure's conduct to come forward, including whistleblowers and former employees [10].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. during the specified Class Period, indicating potential misrepresentation and lack of disclosure regarding the company's drug candidate and regulatory approvals [1][5]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against uniQure - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is alleged that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - The article discusses a securities fraud class action lawsuit against uniQure N.V. due to a significant delay in FDA approval for its drug candidate AMT-130, which led to a 49% decline in the company's stock price [1]. Summary by Relevant Sections Lawsuit Details - Investors who purchased shares of uniQure between September 24, 2025, and October 31, 2025, have until April 13, 2026, to file lead plaintiff applications in the class action lawsuit [1]. - The lawsuit alleges that uniQure and its executives failed to disclose material information, violating federal securities laws [1]. FDA Approval and Stock Impact - During the class period, uniQure indicated a high likelihood of receiving accelerated FDA approval for AMT-130 following a planned Biologics License Application (BLA) submission in Q1 2026 [1]. - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from Phase I/II studies were adequate for BLA submission, resulting in a stock price drop of $33.40, or over 49%, from $67.69 to $34.29 per share [1].

Core Viewpoint - A class action has been filed against uniQure N.V. for allegedly misleading investors regarding the FDA approval likelihood of its leading drug candidate, AMT-130 [1] Allegations - The complaint alleges that uniQure did not fully disclose that the design of its Pivotal Study was not fully approved by the FDA [1] - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline to conduct additional studies [1] Impact of FDA Feedback - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from the Phase I/II studies of AMT-130 would be adequate for BLA submission [1] - Following this announcement, uniQure's stock price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1] Class Action Participation - Shareholders wishing to serve as lead plaintiffs must submit their papers by April 13, 2026 [1] - Participation in the case is not required to be eligible for recovery, and representation is on a contingency fee basis [1]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the effectiveness of its gene therapy candidate AMT-130 and the likelihood of FDA approval [1][3]. Company Overview - uniQure, based in Amsterdam, specializes in developing and commercializing gene therapies for severe diseases, particularly focusing on Huntington's disease and other neurological disorders [2]. Legal Proceedings - The lawsuit pertains to investors who acquired uniQure securities between September 24, 2025, and October 31, 2025, with a deadline of April 13, 2026, for potential lead plaintiff appointments [2]. - The complaint claims that uniQure misrepresented the effectiveness of AMT-130 and the status of FDA agreement on study endpoints, which led to a significant stock price increase of nearly 250% from $13.66 to $47.50 per share shortly after the misleading statements [3]. Stock Performance - Following the revelation on November 3, 2025, that the FDA agreement on study design was not finalized, uniQure's stock plummeted over 49%, dropping from $67.69 to $34.29 per share [4].

Core Viewpoint - A class action lawsuit has been initiated against uniQure N.V. for alleged securities fraud, with a focus on misrepresentations regarding the company's drug candidate and regulatory approvals [1] Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1] - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [1] Group 2: Legal Representation - Rosen Law Firm, known for its success in securities class actions, is leading the lawsuit and encourages investors to select qualified counsel [1] - The firm has a strong track record, having achieved significant settlements for investors, including over $438 million in 2019 [1] - Investors can join the class action by contacting Rosen Law Firm through their website or phone [1] Group 3: Implications for Investors - The lawsuit alleges that when the true details about uniQure's business and operations were revealed, investors suffered damages [1] - A lead plaintiff is needed to represent the class, and interested parties must move the Court by April 13, 2026 [1] - Until the class is certified, investors are not represented by counsel unless they retain one [1]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for securities law violations, specifically for making false and misleading statements regarding its FDA approval process and study design [1] Group 1: Lawsuit Details - The lawsuit pertains to violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is from September 24, 2025, to October 31, 2025, with a deadline for lead plaintiff appointments set for April 13, 2026 [1] - The complaint alleges that uniQure's public statements were materially misleading, particularly regarding the likelihood of delays in its Biologics License Application (BLA) with the FDA due to the need for additional studies [1] Group 2: Company Background - uniQure N.V. is a biotechnology company that focuses on gene therapies [1] - The company is listed on NASDAQ under the ticker symbol QURE [1] - The DJS Law Group, which is handling the lawsuit, specializes in securities class actions and corporate governance litigation [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the efficacy and regulatory approval timeline of its gene therapy AMT-130 for Huntington's disease [1][2] Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, particularly Huntington's disease [1] - The leading drug candidate, AMT-130, aims to slow the progression of Huntington's disease, a fatal genetic disorder with no current cure [1] Clinical Trials and FDA Interaction - uniQure completed patient enrollment for two ongoing Phase I/II clinical trials for AMT-130 in March 2022 [1] - The FDA had previously agreed that the Pivotal Study results could be compared to an external historical dataset (Enroll-HD) instead of using a placebo comparator [1] - The company claimed that the results indicated a significant reduction in neurodegeneration, leading to expectations of accelerated approval from the FDA [1] Stock Performance and Fundraising - Following the announcement of positive topline results on September 24, 2025, uniQure's stock price surged nearly 250%, from $13.66 to $47.50 per share [1] - The company subsequently raised approximately $345 million through a public offering of over 5.7 million shares, despite uncertainties regarding AMT-130's approval timeline [2] Disclosure of Material Information - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Phase I/II studies would support a BLA submission, leading to a stock price drop of over 49% [2] - The lawsuit alleges that uniQure misrepresented the approval status of the Pivotal Study and downplayed the likelihood of delays in the BLA submission process [2]